Real-world clinical outcomes of patients (Pts) with metastatic colorectal cancer (mCRC) who received trifluridine-tipiracil (FTD-TPI) monotherapy or FTD-TPI plus bevacizumab (FTD-TPI plus bev) combination therapy.

被引：0
|
作者：
Nusrat, Maliha
Zhao, Ruizhi
Khan, Nadeem
Wang, Yuexi
Pierre-Victor, Dudith
Tepsick, Jon G.
Sharath, R.
Cann, Christopher G.
Salimi, Tehseen
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Taiho Oncol Inc, Princeton, NJ USA
[3] ConcertAI LLC, Cambridge, MA USA
[4] Fox Chase Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.79
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：79 / 79
页数：1
相关论文
共 45 条
  • [21] Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study
    Nose, Yohei
    Kagawa, Yoshinori
    Hata, Taishi
    Mori, Ryota
    Kawai, Kenji
    Naito, Atsushi
    Sakamoto, Takuya
    Murakami, Kohei
    Katsura, Yoshiteru
    Ohmura, Yoshiaki
    Masuzawa, Toru
    Takeno, Atsushi
    Takeda, Yutaka
    Kato, Takeshi
    Murata, Kohei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (03) : 427 - 433
  • [22] Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study
    Yohei Nose
    Yoshinori Kagawa
    Taishi Hata
    Ryota Mori
    Kenji Kawai
    Atsushi Naito
    Takuya Sakamoto
    Kohei Murakami
    Yoshiteru Katsura
    Yoshiaki Ohmura
    Toru Masuzawa
    Atsushi Takeno
    Yutaka Takeda
    Takeshi Kato
    Kohei Murata
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 427 - 433
  • [23] Impact of colorectal liver metastases (CRLM) in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial
    Tabernero, Josep
    Prager, Gerald W.
    Taieb, Julien
    Calleja, Elizabeth Martine
    Liu, Mei
    Amellal, Nadia
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Clinical Trial Data Review of the Combination FTD/TPI plus Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer
    Andre, Thierry
    Van Cutsem, Eric
    Taieb, Julien
    Fakih, Marwan
    Prager, Gerald W.
    Ciardiello, Fortunato
    Falcone, Alfredo
    Saunders, Mark
    Amellal, Nadia
    Roby, Lucas
    Tabernero, Josep
    Pfeiffer, Per
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (10) : 1312 - 1322
  • [25] Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC)
    Calvo Ferrandiz, A.
    Dahan, L.
    Hollebecque, A.
    Prager, G.
    Andre, T.
    Argiles Martinez, G.
    Bordonaro, R.
    Stein, A.
    Tortora, G.
    Leger, C.
    Amellal, N.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [26] G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study
    Bachet, J-B.
    Bouche, O.
    Trouilloud, I.
    Larnicol, M. L. Garcia
    Vernerey, D.
    Boisson, C.
    Hautefeuille, V.
    Laly, M.
    Rinaldi, Y.
    Fenioux, C.
    Smith, D.
    Desrame, J.
    Lecaille, C.
    Chibaudel, B.
    Wagner, J-P.
    Texereau, P.
    Vienot, A.
    Tougeron, D.
    Borg, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S447 - S447
  • [27] Preclinical analysis and clinical validation to identify biomarkers for trifluridine/tipiracil (FTD/TPI) efficacy with or without bevacizumab in patients with metastatic colorectal cancer.
    Suenaga, Mitsukuni
    Mashima, Tetsuo
    Kawata, Naomi
    Dan, Shingo
    Seimiya, Hiroyuki
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 230 - 230
  • [28] Relationship between fluoropyrimidine (FPD) exposure and outcomes in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial.
    Fakih, Marwan
    Prager, Gerald W.
    Taieb, Julien
    Calleja, Elizabeth Martine
    Liu, Mei
    Amellal, Nadia
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 114 - 114
  • [29] JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies
    Kazama, K.
    Nakamura, M.
    Tanaka, R.
    Ojima, H.
    Makiyama, A.
    Matsuhashi, N.
    Kagawa, Y.
    Okuda, H.
    Asayama, M.
    Yuasa, Y.
    Negoro, Y.
    Mushiake, H.
    Manaka, D.
    Oba, K.
    Yoshino, T.
    Yoshida, K.
    Maehara, Y.
    Yamazaki, K.
    Oki, E.
    Takahashi, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 234 - 234
  • [30] TALLISUR Phase IV study of trifluridine/tipiracil (FTD/TPI) in patients with pre-treated metastatic Colorectal Cancer (mCRC) - subgroup analysis
    Karthaus, M.
    Weiss, L.
    Riera-Knorrenschild, J.
    Kretschmar, A.
    Welslau, M.
    Vehling-Kaiser, U.
    Pelz, H.
    Ettrich, T.
    Held, S.
    Klein, A.
    Hess, J.
    Reislaender, T.
    Heinemann, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 160 - 160
12345